Search

Home > GRACEcast Lung Cancer Video > Perhaps Rash SHOULD be a Critical Factor in Clarifying Who Benefits from an EGFR Inhibitor: The TOPICAL Study
Podcast: GRACEcast Lung Cancer Video
Episode:

Perhaps Rash SHOULD be a Critical Factor in Clarifying Who Benefits from an EGFR Inhibitor: The TOPICAL Study
Category: Science & Medicine
Duration: 00:06:38
Publish Date: 2012-11-25 02:18:02
Description:

Dr. H. Jack West reviews the TOPICAL study of Tarceva vs. placebo for marginal and poor PS patients with advanced NSCLC, which showed a clearly superior outcome with Tarceva in patients who developed a rash vs. those who don't.
Total Play: 0